With 6.2% CAGR, Intravenous Immunoglobulins Market Size worth USD 15,789.1 Million in 2025
Fortune Business Insights
5 min read
Fortune Business Insights
According to Fortune Business Insights, Intravenous Immunoglobulins Market was worth US$ 9,787.6 Mn. The market is anticipated to further expand at a CAGR of 6.2% and reach US$ 15,789.1 by the end of 2025. Intravenous Immunoglobulin Application in Hospitals to Rise Persistently
Pune, India, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The global prevalence of primary immunodeficiency is rising, giving impetus to the global intravenous immunoglobulins market. A report is published by Fortune Business Insights, titled “Intravenous Immunoglobulins: Global Market Analysis, Insights and Forecast, 2018-2025,” offers in-depth insights into the market. As per the report, in 2017 the global market was worth US$ 9,787.6 Mn. The market is anticipated to further expand at a CAGR of 6.2% and reach US$ 15,789.1 by the end of 2025.
In terms of indication, the report classifies the global market in primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), and others. Primary immunodeficiency was leading the market in 2017. The segment accounted for 28.6% of the global market in 2017. During the forecast period 2018-2025, the segment is likely to witness expansion at an impressive pace. Diagnosis of primary immunodeficiency is gaining momentum and encouraging the adoption of intravenous immunoglobulins. Moreover, patients who are incapable to perform self-intervention of immunoglobulin are further generating high demand in the intravenous immunoglobulins market. Besides this, the chronic inflammatory demyelinating polyneuropathy segment is forecast to show a slower growth owing to the low prevalence of the disease the segment may witness slow growth.
Intravenous Immunoglobulin Application in Hospitals to Rise Persistently
Intravenous immunoglobulin is the most common route of administration of immunoglobulins, which is the chief driver of the global market. The rising demand from hospitals and specialty clinics is anticipated to encourage the adoption of intravenous immunoglobulins. Furthermore, key companies are increasingly investing in research and development of advanced intravenous immunoglobulins. Such researches are likely to enable growth in the market over the forecast period.
Immunoglobulins are proven to be one of the best treatment options for various immune diseases. Owing to the high popularity of immunoglobulins, the market is foreseen to witness high demand.
On the contrary, factors that may restrain the global intravenous immunoglobulins market are side effects associated with intravenous immunoglobulins and intravenous immunoglobulin’s high cost.
North America to Continue Dominating Global Market
The North America intravenous immunoglobulins market was worth US$ 5,587.4 Mn in 2017. The region is further expected to emerge dominant over the forecast period. The increasing number of patients in the region is anticipated to drive the regional market. Moreover, in terms of dominance of route of administration, intravenous (IV) is the most dominating type in developing nations. This is likely to enable growth in market. Besides this, the advanced intravenous immunoglobulins are being rapidly adopted in developed nations. This in response is fueling the demand in market. Asia Pacific is anticipated to expand at a promising CAGR. Owing to the high prevalence of primary immunodeficiency in Asian population, the market is foreseen to witness demand for immunoglobulin.
The competition among the key players is increasing. Owing to the prevailing opportunities, players are focusing on the adoption of innovative strategies to gain a strong brand presence. In 2017 Grifols, S.A. was leading the global market owing to its diverse product portfolio. The Grifols, S.A. also holds a major share in the European and North America intravenous immunoglobulins market. Other key companies operating in the global intravenous immunoglobulins market are CSL Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA and Shanghai RAAS Blood Products Co., Ltd.
How Much Intravenous Immunoglobulins Market Worth ?
Intravenous Immunoglobulins Market was worth US$ 9,787.6 Mn. The market is anticipated to further expand at a CAGR of 6.2% and reach US$ 15,789.1 by the end of 2025.
What are the key factor driving the market ?
The global intravenous immunoglobulins market are side effects associated with intravenous immunoglobulins and intravenous immunoglobulin’s high cost.
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
